46-60 of 282
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstractsOptimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Ryan Quigley
Kathrin M. Bernt, MD
Rushabh Mehta, BS
Fatemeh Alikarami
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's RoundtableImproving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Charles Turck, PharmD, BCPS, BCCCP
Caterina Garone, MD, PhD
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Clinician's RoundtableUncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Charles Turck, PharmD, BCPS, BCCCP
Cristina Domínguez González, MD, PhD
- advertisement
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's RoundtableUnderstanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Charles Turck, PharmD, BCPS, BCCCP
Philip Yeske, PhD
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CMManaging Genotype-Positive Patients in Hereditary ATTR-CM
Shelina Ramnarine, PhD
Naveen L. Pereira, MD
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiersLUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
- advertisement
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
The Cost of Progress: Examining Barriers to ATTR-CM Care
On the Frontlines of ATTR-CMThe Cost of Progress: Examining Barriers to ATTR-CM Care
Charles Turck, PharmD, BCPS, BCCCP
Michelle Kittleson, MD, PhD
